ImageneBio (IMA) Total Debt (2023 - 2024)
ImageneBio (IMA) posted Total Debt of $8.6 million for Q4 2024, up 801.16% sequentially from $950000.0 in Q4 2023, and up 801.16% YoY from $950000.0 in Q1 2024.
ImageneBio (IMA) Total Debt (2023 - 2024) Analysis & Trends
ImageneBio has reported Total Debt for 2 years, with the latest figure at $8.6 million in Q4 2024.
- Quarterly Total Debt rose 801.16% year-over-year to $8.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $8.6 million (up 801.16% YoY) and the FY2024 annual result came in at $8.6 million, up 801.16% from the prior year.
- Total Debt climbed to $8.6 million in Q4 2024 per IMA's latest filing, from $950000.0 in the prior quarter.
- Over five years, Total Debt peaked at $8.6 million in Q4 2024 and troughed at $852000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.34 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 770.36 Mn |
| 10 | ImageneBio | 48.60 Mn | -86.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 8.56 Mn |
| Dec 31, 2023 | 950,000.00 |
| Sep 30, 2023 | 852,000.00 |